CancerNetwork®

🚨 We're dropping a whole new podcast! 🚨 🎙️ Hosted by Brandon Mancini, MD, MBA, FACRO (@brandonmancini), listen to the debut episode of RadOnc on the Run, "Taking the First Steps Beyond the Starting Line". hubs.li/Q03_nSXR0 #RadOnc #Oncology #RadiationOncology #Cancer

Investigators found that 10.6% of patients developed a new MHD within 1 year of their cancer diagnosis. We spoke with Julian Hong, MD, MS, about these findings and more 👇👇 hubs.li/Q047rZ3c0 #cancer #oncology #MentalHealth | @julian_hong

The "Quick Take" from #APOS2026 is here! 🎥 From suicide risk to sleep disturbances and cognitive impairment, we’re recapping the essential psychosocial oncology updates from New Orleans. Check out the highlights and visit CancerNetwork.com for more in-depth coverage. 📑 @APOSHQ

Persistent training and workflow gaps were noted across the psychosocial domains for adolescent and young adult cancer care. ⭐ Awareness alone was shown to be insufficient for developmentally appropriate care. hubs.li/Q047rYCb0 #Oncology #Cancer #APOS26

Day 2 of #APOS26! Stop by our table to say hi, and share your insights in oncology publishing, there might be a prize in store for you! @APOSHQ @cure_today

MyChoice CDx is now the only FDA-approved companion diagnostic test to identify treatment-eligible patients with HRD-positive status for niraparib treatment eligibility. ⬇️ Read more ⬇️ hubs.li/Q047rLLx0 #gyncsm #OvarianCancer #Oncology

The AI Oncology Revolution is coming soon ✨ This will be an exclusive YouTube series to give a deeper dive into exploring the application of artificial intelligence, AI, into clinical practice. Want to be a guest, or have topic ideas for this series? Comment below or DM 🎥 @MJHLifeSciences @CancerNetwrk @mystlukes @ASCO @AmericanCancer @MassiveBio

We CANNOT wait to launch this series with you @DrArturoAI! Let us know if you want to appear alongside him 👀

🫁 Pembrolizumab showed long-term survival improvements vs chemotherapy in PD-L1–positive NSCLC. Five-year follow-up data from the phase 3 KEYNOTE-042 China study further support pembrolizumab monotherapy as a standard of care. For more updates in lung cancer, check out cancernetwork.com. #lcsm #pembrolizumab #oncology

🎥Lots of live interviews coming out of #APOS26 •Benjamin Brewer, PsyD, on sleep-wake distrubances •Yesne Alici, MD, on cognitive decline •Chiara Acquati, PhD, on sexual health in AYA survivors @APOSHQ

⏳New podcast episode loading Filmed live at #APOS26 discussing suicide risk in patients with cancer While you wait, catch up on the latest psycho-onc episode today: cancernetwork.com/podcasts/danie…

Some moments from #APOS26 opening session, a packed room! @APOSHQ

For patients with medically-inoperable uterus treated with combined external beam radiotherapy and brachytherapy, quality of life outcomes, like sexual health and urinary-related toxicity, are prioritized. #gyncsn #EndometrialCancer #RadOnc #Oncology

🎥We’re live in New Orleans for #APOS26 meeting with some great thought leaders in the psycho-oncology space. @APOSHQ

Developers announced a productive Type B meeting with the FDA for givastomig’s potential eligibility and pathway to accelerated approval in 1L HER2–, CLDN18.2+, PD-L1+ gastroesophageal cancer. hubs.li/Q047dHZN0 #GastricCancer #Gastrointestinal #Oncology #Cancer

All patients with low-to-intermediate risk, localized prostate cancer underwent successful implantation with the enzalutamide-containing anti-androgen eluting implant Enolen. ⭐ Pre-radical prostatectomy MRIs showed an 84% reduction in tumor volume among 18 patients over an average duration of 35 days. ⭐ All implantations achieved high intraprostatic enzalutamide levels with minimal systemic drug exposure, resulting in no delays to surgery. hubs.li/Q046_nJ60 #pcsm #ProstateCancer #Oncology

🧬 Frontline BCMA-directed therapy showed enduring remissions among patients with newly diagnosed multiple myeloma not eligible for ASCT. Data from a phase 2 trial in China support a “potential paradigm shift” for a vulnerable population. For more coverage of the latest advances in myeloma, visit cancernetwork.com. #mmsm #BCMA #oncology

Patients with cancer who had a mental health condition were at higher risk of all-cause mortality. 💠 Most prevalent cancer sites in study: breast, prostate, hematologic 💠 Cancers with lower survival rates associated with new mental helath disorder diagnosis Stay tuned for more coverage on this study 🔜 #MentalHealth #Cancer #Oncology

An independent data monitoring committee recommended that investigators terminate the trial of eftilagimod alfa plus pembrolizumab/chemotherapy in 1L NSCLC for futility. 💠 Trial enrollment will be halted. 💠 Orderly wind-down will be conducted. hubs.li/Q046_5NB0 #lcsm #NSCLC #LungCancer #Oncology

Check out the @CancerNetwrk video commentary by @WCMEnglanderIPM's Dr. Scott T. Tagawa (@DrScottTagawa) who evaluated how the #rPFS improvement with #lutetium-177 could help integrate the treatment into the frontline metastatic #HSPC setting! cancernetwork.com/view/redefinin…